Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.

William WN Jr, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ; University of Texas M.D. Anderson Lung Cancer Collaborative Research Group.

J Thorac Oncol. 2013 Feb;8(2):222-8. doi: 10.1097/JTO.0b013e3182774108.

2.

Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.

Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG; University of Texas M. D. Anderson Lung Cancer Collaborative Research Group.

J Thorac Oncol. 2012 May;7(5):825-32. doi: 10.1097/JTO.0b013e318247504a.

3.

Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.

Liao WY, Chen JH, Wu M, Shih JY, Chen KY, Ho CC, Yang JC, Yu CJ.

Clin Lung Cancer. 2013 Jul;14(4):418-24. doi: 10.1016/j.cllc.2012.10.003. Epub 2013 Jan 4.

PMID:
23291258
4.

Assessing response to treatment in non--small-cell lung cancer: role of tumor volume evaluated by computed tomography.

Knollmann FD, Kumthekar R, Fetzer D, Socinski MA.

Clin Lung Cancer. 2014 Mar;15(2):103-9. doi: 10.1016/j.cllc.2013.11.001. Epub 2013 Nov 13.

PMID:
24361250
5.

A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.

Lv C, Ma Y, Wu N, Yan S, Zheng Q, Sun Y, Li S, Fang J, Yang Y.

World J Surg Oncol. 2013 Mar 21;11:76. doi: 10.1186/1477-7819-11-76.

6.

Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.

Lee HY, Lee HJ, Kim YT, Kang CH, Jang BG, Chung DH, Goo JM, Park CM, Lee CH, Kang KW.

J Thorac Oncol. 2010 Apr;5(4):497-503. doi: 10.1097/JTO.0b013e3181d2efe7.

7.

Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer.

He L, Teng Y, Jin B, Zhao M, Yu P, Hu X, Zhang J, Li S, Gao Y, Liu Y.

BMC Cancer. 2010 Dec 14;10:681. doi: 10.1186/1471-2407-10-681.

8.

Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.

Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P, Ducoloné A, Molinier O, Zalcman G, Depierre A, Westeel V; Intergroupe Francophone de Cancérologie Thoracique (IFCT).

J Thorac Oncol. 2012 May;7(5):841-9. doi: 10.1097/JTO.0b013e31824c7d92.

9.

Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.

Shimizu K, Yukawa T, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M.

World J Surg Oncol. 2015 Feb 6;13:21. doi: 10.1186/s12957-014-0426-0.

10.

Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis.

Malhotra J, Mhango G, Gomez JE, Smith C, Galsky MD, Strauss GM, Wisnivesky JP.

Ann Oncol. 2015 Apr;26(4):768-73. doi: 10.1093/annonc/mdv008. Epub 2015 Jan 18.

PMID:
25600562
11.

Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.

Stojsic J, Stankovic T, Stojkovic S, Milinkovic V, Dinic J, Milosevic Z, Milovanovic Z, Tanic N, Bankovic J.

Exp Mol Pathol. 2015 Feb;98(1):27-32. doi: 10.1016/j.yexmp.2014.11.010. Epub 2014 Nov 20.

PMID:
25449334
12.

Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung.

Chaft JE, Sima CS, Ginsberg MS, Huang J, Kris MG, Travis WD, Azzoli CG.

J Thorac Oncol. 2012 Sep;7(9):1400-5. doi: 10.1097/JTO.0b013e3182614856.

13.

Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.

Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L.

Clin Lung Cancer. 2013 Jul;14(4):433-9. doi: 10.1016/j.cllc.2013.01.004. Epub 2013 Mar 22.

PMID:
23522953
15.

A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor.

Yamane Y, Ishii G, Goto K, Kojima M, Nakao M, Shimada Y, Nishiwaki Y, Nagai K, Kohrogi H, Ochiai A.

J Thorac Oncol. 2010 Jan;5(1):49-55. doi: 10.1097/JTO.0b013e3181c0a1f8.

16.

Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.

Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.

Acta Oncol. 2012 May;51(5):636-44. doi: 10.3109/0284186X.2011.643822. Epub 2012 Jan 2.

PMID:
22208782
17.

Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).

Kocher F, Pircher A, Mohn-Staudner A, Romeder F, Duller W, Steinmaurer M, Eckmayr J, Schmid T, Hilbe W, Fiegl M, Greil R.

Lung Cancer. 2014 Sep;85(3):395-400. doi: 10.1016/j.lungcan.2014.06.019. Epub 2014 Jul 3.

PMID:
25043642
18.

CT Signs Can Predict Treatment Response and Long-Term Survival: A Study in Locally Advanced Esophageal Cancer with Preoperative Chemotherapy.

Zhang XY, Yan WP, Sun Y, Li XT, Chen Y, Fan MY, Wu Y, Liang Z, Xiong HC, Wang ZL, Sun YS, Chen KN.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1380-7. doi: 10.1245/s10434-015-4531-2. Epub 2015 May 5.

PMID:
25940570
19.

A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.

Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR.

J Thorac Oncol. 2012 Mar;7(3):574-8. doi: 10.1097/JTO.0b013e31823f43ca.

20.

Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.

Koshy M, Fedewa SA, Malik R, Ferguson MK, Vigneswaran WT, Feldman L, Howard A, Abdelhady K, Weichselbaum RR, Virgo KS.

J Thorac Oncol. 2013 Jul;8(7):915-22. doi: 10.1097/JTO.0b013e31828f68b4.

Supplemental Content

Support Center